COMPANY PROFILE

DSCi Lab

Explore full profile

Specialized in the research and development of lipid-based delivery systems and messenger ribonucleic acid therapeutics

Suzhou Shi, ChinaFounded 2022Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Total funding $10–50M Disclosed equity funding

Unlock exact values

About DSCi Lab

DSCI Laboratory specializes in the development of lipid-based nanocarriers and mRNA therapeutics aimed at addressing significant clinical needs. Operating in the biotechnology and pharmaceutical sectors, the company serves clients ranging from research institutions to healthcare providers. DSCI Laboratory's business model focuses on creating proprietary lipid nanoparticle (LNP) delivery systems and mRNA drugs, which are essential for targeted drug delivery and advanced therapeutic applications. Revenue is generated through the development and licensing of these technologies, as well as through partnerships and collaborations with other biotech firms and pharmaceutical companies. The company is incubated by Fosun Health Capital, which provides both financial backing and strategic support. DSCI Laboratory is committed to setting up a comprehensive platform for early-stage drug discovery and manufacturing, ensuring a robust pipeline of unique and competitive products.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Suzhou Shi, China
Open positions: None listed
Dealroom signal: 21.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Genetics and genomics, Biotech and Pharma, mRNA Medicines, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Oct 2025	—	—	Fosun Health Capital · Jenkem Technology	↗
SEED✓Equity / VC	May 2024	$14M	$55M	Shanghai Creation Investment · Fosun Health Capital	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

DSCi Lab website traffic

Latest recorded traffic for DSCi Lab is 90 monthly website visits, down 85.5% over the last three months.

Latest monthly visits90 3-month web change-85.5%

Monthly website visitsJun 2024–Oct 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ABAvenue BiosciencesInnovative protein engineering solutions integrating biologics and machine learning for therapeutic advancements	Palo Alto, United States	Operational	23	$8.2M	$23M
RMRVAC MedicinesMRNA platform company engaged in the research and development of innovative products such as vaccines for diseases	Singapore	Operational
VBVernal BiosciencesManufacturer of high purity mRNA for research and clinical use	Colchester, United States	Operational
ZVZiphius VaccinesAddresses urgent global public health needs by developing mRNA-based vaccines	Ghent, Belgium	Operational
DEDeepflareDeepflare is an AI company helping pharma firms accelerate cancer vaccine and immunotherapy development	Warsaw, Poland	Operational
ESEsperovaxEsperovax is working to create vaccines for some of the world’s most deadly diseases	Plymouth Township, United States	Operational
INInflammatixDeveloping novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system	Sunnyvale, United States	Operational
EXExonateTopical small-molecule therapeutics for retinal vascular diseases	Cambridge, United Kingdom	Operational